Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2007

Filing Date
Filed February 11, 2008
Period End
December 31, 2007
Security
NBIX
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Sep ’19Sep ’19
  3. Material agreement8-K · Nov ’21Nov ’21
  4. Leadership change8-K · Nov ’25Nov ’25

Summary

Summary of the 10-K filed February 11, 2008. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. (NBIX) reported a net loss of $207.3 milliona for 2007, or $5.45 per share, compared with $107.2 million in 2006.

Total revenues fell to $1.2 millionb from $39.2 million, reflecting the absence of Pfizer collaboration revenue recognized in 2006. The loss includes a $94.0 million non-cash impairment of a prepaid royalty on indiplon, recorded after the FDA issued a second approvable letter in December 2007. The company has no marketed products, reports an accumulated deficit of $614.7 million, and states it does not expect to be profitable in 2008.

The company's regulatory outlook for its lead insomnia candidate, indiplon, is uncertain. The FDA's December 12, 2007 approvable letter for the 5mg and 10mg capsules set new requirements, including an elderly clinical trial, a safety study versus a marketed product, and a preclinical third-trimester pregnancy study. The company ceased indiplon clinical development and pre-commercialization activities in the U.S., and the 15mg tablets remain not approvable.

Indiplon rights in Japan were licensed to Dainippon Sumitomo Pharma for a $20.0 million upfront fee, with up to $115.0 millionc in additional milestones possible. The pipeline centers on a GnRH antagonist for endometriosis, with a Phase IIb study expected to report top-line results in mid-2008, and CRF1 antagonist work partnered with GlaxoSmithKline. The company cut costs through a December 2007 restructuring of about 125 employees, expected to reduce annual expenses by approximately $18.0 million, and a sale-leaseback of its San Diego facility for $109.0 million.

Cash, cash equivalents and short-term investments totaled $179.4 milliond at year-end, and management believes existing resources are sufficient for at least the next 12 months. Securities class action and derivative lawsuits related to indiplon are pending.

Key Highlights

  1. Net loss of $207.3 million ($5.45 per share) in 2007, including a $94.0 million non-cash prepaid royalty impairment on indiplon
  2. Total revenues of $1.2 million in 2007, down from $39.2 million in 2006
  3. FDA issued a 2007 approvable letter for indiplon 5mg and 10mg capsules with new requirements; 15mg tablets remain not approvable; U.S. indiplon development activities ceased
  4. Licensed indiplon rights in Japan to Dainippon Sumitomo Pharma for a $20.0 million upfront fee, with up to $115.0 million in additional milestones
  5. GnRH antagonist for endometriosis in Phase IIb study; top-line results expected mid-2008
  6. Cash, cash equivalents and short-term investments of $179.4 million; accumulated deficit of $614.7 million
  7. December 2007 restructuring of about 125 employees, expected to reduce annual expenses by approximately $18.0 million; San Diego facility sold for $109.0 million in a sale-leaseback

Frequently Asked Questions

  1. Why did Neurocrine's net loss increase so significantly in 2007?

    The net loss rose to $207.3 million from $107.2 million, primarily due to a $94.0 million non-cash impairment of the prepaid royalty on indiplon, recorded after the FDA's December 2007 approvable letter created significant uncertainty about indiplon's future development. Revenues also fell to $1.2 million from $39.2 million, as 2006 included Pfizer collaboration revenue.

  2. What are the regulatory prospects for indiplon?

    The FDA deemed the 5mg and 10mg capsules approvable in December 2007 but required an objective/subjective clinical trial in the elderly, a safety study comparing adverse event rates with a marketed product, and a preclinical study of administration in the third trimester of pregnancy. The 15mg tablets were deemed not approvable. The company requested a formal meeting with the FDA in the first quarter of 2008 and ceased U.S. indiplon clinical and pre-commercialization activities.

  3. Does Neurocrine have enough cash to fund operations?

    Cash, cash equivalents and short-term investments totaled $179.4 million at December 31, 2007. Management believes existing capital resources, interest income and future payments under strategic alliances will be sufficient for at least the next 12 months, though it also notes that it has an effective shelf registration for up to $150 million in securities and that additional equity financing would be dilutive.

  4. What are the company's most important pipeline programs?

    The lead program is a non-peptide oral GnRH antagonist for endometriosis, with a Phase IIb trial of 252 patients completed enrollment in Q4 2007 and top-line results expected in mid-2008. CRF1 antagonist programs for mood disorders and irritable bowel syndrome are advanced by GlaxoSmithKline, with IBS data expected in the second half of 2008. A Urocortin 2 program for chronic heart failure is in Phase II.

  5. What pending legal matters could affect the company?

    A consolidated federal securities class action (In re Neurocrine Biosciences, Inc. Securities Litigation) alleges false and misleading statements about indiplon's FDA progress and market potential in the 15mg dosage. A motion to dismiss was filed January 11, 2008, with a hearing scheduled for April 7, 2008. A related shareholder derivative suit has been stayed pending that resolution. The company states the financial impact cannot currently be reasonably estimated.